A randomized, non-comparative, multicenter phase II trial of neoadjuvant becotatug vedotin alone or combined with immune checkpoint inhibitors (penpulimab/ivonescimab) in resectable locally advanced head and neck squamous cell carcinoma.
Xiaoyuan Wei(Beihang University), Lu Liu(Henan Agricultural University), Yuanyuan Zeng(Sichuan University), Zhongzheng Xiang(Sichuan University), Yi-Xiang Wang(Chinese Academy of Sciences)
Cited by 0
Related Papers
Multifunctional biohybrid magnetite microrobots for imaging-guided therapy
|Science Robotics|2017|873
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
|International Journal of Oncology|2016|385
Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer
|Molecular Cancer|2018|369
PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
|International Journal of Clinical Oncology|2017|315
JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells
|International Journal of Oncology|2014|314